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Abstract
Background: Crusted scabies, or hyperinfestation with Sarcoptes scabiei, occurs in people with an inadequate immune
response to the mite. In recent decades, data have emerged suggesting that treatment of crusted scabies with oral
ivermectin combined with topical agents leads to lower mortality, but there are no generally accepted tools for describing
disease severity. Here, we describe a clinical grading scale for crusted scabies and its utility in real world practice.
Methodology/Principal Findings: In 2002, Royal Darwin Hospital (RDH), a hospital in tropical Australia developed and
began using a clinical grading scale to guide the treatment of crusted scabies. We conducted a retrospective observational
study including all episodes of admission to RDH for crusted scabies during the period October 2002–December 2010
inclusive. Patients who were managed according to the grading scale were compared with those in whom the scale was not
used at the time of admission but was calculated retrospectively. There were 49 admissions in 30 patients during the study
period, of which 49 (100%) were in Indigenous Australians, 29 (59%) were male and the median age was 44.1 years.
According to the grading scale, 8 (16%) episodes were mild, 24 (49%) were moderate, and 17 (35%) were severe.
Readmission within the study period was significantly more likely with increasing disease severity, with an odds ratio (95%
CI) of 12.8 (1.3–130) for severe disease compared with mild. The patients managed according to the grading scale (29
episodes) did not differ from those who were not (20 episodes), but they received fewer doses of ivermectin and had a
shorter length of stay (11 vs. 16 days, p = 0.02). Despite this the outcomes were no different, with no deaths in either group
and a similar readmission rate.
Conclusions/Significance: Our grading scale is a useful tool for the assessment and management of crusted scabies.
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Introduction
Scabies is a parasitic infestation caused by the mite Sacroptes
scabiei var hominis. Globally, over 300 million people are estimated
to be affected [1]. The mite is endemic in disadvantaged and
impoverished communities [2,3]. In Australia Indigenous people
suffer a significant disadvantage in health outcomes compared
with non-Indigenous Australians [4,5], and scabies is endemic in
many Indigenous communities in northern Australia, with a recent
survey demonstrating a mean prevalence of 13.4% in five remote
Indigenous communities [6].
Crusted scabies (also known as ‘‘Norwegian scabies’’) is
hyperinfestation with the Sarcoptes scabiei mite, and is characterized
by a non-protective host immune response, the development of
hyperkeratotic skin crusts and skin fissuring [7]. It is a severe
disease with a significantly higher mortality than ordinary scabies.
Unlike ordinary scabies, where there are usually less than 20 mites
on the host’s entire skin, individuals with crusted scabies can have
up to 4000 mites per gram of skin and are extremely infectious to
others [8,9]. Despite the severity of the disease there is significant
variability in the clinical presentation, and there is currently no
generally accepted method of describing the severity of a crusted
scabies infection.
The optimal treatment for crusted scabies has not been subjected
to a comparative trial and is generally based on expert opinion
[10,11]. However observational data suggest that the use of multiple
doses of oral ivermectin as therapy for crusted scabies can lead to a
significant decline in mortality [9,12,13]. In an attempt to formalize
and improve the treatment of crusted scabies, we developed a
grading scale, based on our clinical experience in managing such
patients. This was introduced into routine clinical use at our
hospital in 2002, and has been used since this time to titrate the
duration of ivermectin and topical therapy to illness severity.
Here, we describe the grading scale and our experience with it
over the first eight years of its use. We aimed to evaluate the utility
of the grading scale, including its correlation with other putative
markers of illness severity, the safety of its use and the effect on
length of stay and relapse rates.
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Methods
Ethics statement
The study was approved by the human research ethics
committee of the Menzies School of Health Research and
Northern Territory Department of Health.
Study setting
350 bed tertiary referral hospital in the tropical Northern
Territory, Australia, serving a population of approximately
150,000 people spread over an area of 500,000 km2, including
many remote Indigenous communities. Local policies encourage
the hospitalization of patients with crusted scabies for clinical
management, as well as environmental health input to address the
risk of ongoing transmission in an index patient’s household. The
standard treatment protocol for crusted scabies includes prolonged
hospitalization in a single room with contact precautions, the use
of topical benzyl benzoate plus 5% tea tree oil 2–3 times per week
[14], multiple doses of oral ivermectin (as described below), topical
keratolytics, systemic antibacterial drugs where judged clinically
necessary, and attention to medical comorbidities.
Participants
All patients admitted to our hospital with a discharge diagnosis
of crusted scabies between 1st of October 2002 and 31st of
December 2010 were included in the study. Crusted scabies was
diagnosed based on the clinical opinion of an Infectious Diseases
specialist, supplemented by skin scrapings demonstrating S. scabiei
mites on microscopy.
Severity grading scale
The grading scale for crusted scabies is shown in Figure 1. It is
based on clinical assessment in four key areas: the distribution and
extent of crusting; the depth of crusting; the degree of skin
cracking and pyoderma; and the number of previous episodes.
This scale was developed in 2002 by two of the authors (JD and
BC) for use with all patients hospitalised with crusted scabies. It
was partly based on previous local experience that multiple doses
of ivermectin in addition to topical treatment were more effective
than topical treatment alone for the treatment of crusted scabies
[9]. Other studies have confirmed the efficacy of the combination
of ivermectin and topical therapy for crusted scabies [13,15,16].
During the study period medical staff managing patients with
crusted scabies were encouraged but not compelled to use the
grading scale to guide management. Therefore we were able to
compare those patients in whom the grading scale was applied at
the time of the patient’s clinical presentation to those in whom the
grading scale was not used and then calculated retrospectively by
the authors.
Data definitions, collection and analysis
We reviewed clinical notes, bedside charts and the hospital’s
clinical pathology database for each patient using a standardized
case record form. We collected data on demographics, comorbid-
ities, disease severity, grading scale and outcomes. Where the
grading scale had not been prospectively documented, we
calculated it based on the detailed clinical information found in
the medical record. Each admission (rather than each individual
patient) was counted as a discrete episode. Where a patient had
more than one admission during the study period, it was only
counted as a separate episode if at least 30 days had elapsed from
the previous date of discharge. Iatrogenic immunosuppresion was
defined as the use of any of the following medications within the
past 3 months: prednisolone $0.5 mg/kg/day or equivalent for at
least 14 days; immunosuppresion for solid organ transplant; cancer
chemotherapy; immunosuppressive monoclonal antibody use; any
other use of azathioprine, methotrexate, leflunomide, cyclospor-
ine, mycophenolate, or cyclophosphamide. Hazardous alcohol use
was defined as an average of.4 standard drinks per day for a man
or .2 for a woman. Chronic renal disease was defined as an
estimated glomerular filtration rate of less than 30 ml/min, or the
need for dialysis.
Data were entered into a purpose-built database using Epidata v
3.0 and were analysed using Stata version 10 (Statacorp, College
Station, Texas, USA). Categorical variables were compared using
Fisher’s exact test, and continuous using Mann-Whitney-U test.
Correlations were assessed using Spearman’s rank correlation. P
values of ,0.05 were considered significant
Results
Demographics and comorbidities
There were 49 admissions for crusted scabies in 30 patients
during the eight year study period. Of the episodes, 49 (100%)
were in Indigenous Australians, 29 (59%) were male and the
median age at the time of the first admission within the study
period was 45.4 years (Table 1). Most of the patients lived in
remote areas, and iatrogenic immunosuppresion was rare.
Patient management
All patients received at least one dose of oral ivermectin (with a
mean of 5.2 doses, and a range of 2 to 10). 47 patients (95%) were
treated with topical benzyl-benzoate in combination with 5% tea-
tree oil, and the remainder with topical permethrin. In addition,
all patients were treated with topical Calmurid (lactic acid and
urea in sorbolene cream, used as a keratolytic). Systemic
antibiotics were used in 38 (79%) of episodes.
Disease severity and outcomes
According to the grading scale, 8 (16%) episodes were mild
(grade 1), 24 (49%) were moderate (grade 2), and 17 (35%) were
severe (grade 3). Seven episodes (14%) were complicated by
bacteraemia, with the causative organism being Staphylococcus aureus
in 6 patients, and a mixed infection with Group A streptococcus
and Escherischia coli in 1. The disease severity according to the
grading scale did not correlate with the proportion of patients with
bacteremia, or with the peak plasma C-reactive protein during the
admission (table 2). However, there was a non-significant trend
Author Summary
Crusted scabies is a severe skin condition caused by a
microscopic parasitic mite. It occurs in people whose
immune system does not react properly to the mite and it
leads to crusting and cracking of the skin and can cause
death. The usual treatment for crusted scabies is a tablet
called ivermectin combined with anti-scabies skin creams.
However, there is no current method of measuring the
severity of crusted scabies and thus deciding how long to
continue the treatment for. We have developed a grading
scale based on examination of the skin, which classifies
patients as mild, moderate or severe, and uses this grading
to suggest the duration of treatment. We have trialed this
grading scale over an 8-year period in 49 episodes of
crusted scabies requiring hospital admission, and have
found that it leads to a shorter length of hospital stay and
treatment, but equivalent outcomes compared to those
who were treated without the use of the grading scale.
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towards lower nadir plasma albumin and longer hospital stay with
higher severity (table 2). No patients in this cohort died during the
hospital admission, but a substantial proportion (47%) required
readmission for crusted scabies within the eight year study period.
Readmission was significantly more likely with increasing disease
severity, with an odds ratio (95% CI) of 5.9 (0.7–55.9) for
moderate disease compared with mild, and 12.8 (1.3–130) for
severe disease compared with mild.
Effect of prospective use of the grading scale
There was no significant difference in age, gender, location of
residence or comorbidities between those patients who had the
severity score calculated at the time of admission (n= 29) and those
who did not (n = 20). Episodes where the grading scale was
calculated at the time of admission had a significantly shorter
length of stay, and received fewer doses of ivermectin than those
not managed using the grading scale (Table 3). Despite this their
outcomes were no different, with no deaths in either group, and a
similar readmission rate in the two groups.
Discussion
This is the first published description of a clinical severity
grading scale for use in patients with crusted scabies. The use of
Figure 1. Severity grading scale for crusted scabies.
doi:10.1371/journal.pntd.0002387.g001
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this grading scale in our setting is associated with good outcomes
despite shorter hospital stays and less ivermectin use compared
with those managed without the use of the grading scale.
Crusted scabies is a severe disease with significant morbidity and
mortality which is more prevalent in communities such as remote-
dwelling Australian Indigenous people [2]. Crusted scabies is
usually reported as occurring in patients who are immunosup-
pressed, either iatrogenically [17,18,19,20] or by retroviral
infection [21,22,23]. In our cohort there was a high rate of
hazardous alcohol use, diabetes and chronic renal disease, but only
16% of episodes were associated with iatrogenic immunosuppre-
sion or HTLV-1 infection. This reinforces the findings of previous
studies that, in Indigenous Australians, the majority of people with
crusted scabies do not meet the generally accepted definitions of
significant immunosuppression and suggests that the immune
defect in patients with crusted scabies is subtle and probably
multifactorial [8].
Our grading scale did not correlate with many of the putative
measures of disease severity we used (CRP, ICU admission,
bacteraemia). However, these factors are really measures of the
sequelae of crusted scabies and there is no generally accepted
single marker of disease severity in this setting (hence the need for
the clinical grading scale). The degree of systemic inflammation
and risk of bacteraemia are likely to relate to multiple factors,
including the patient’s immune responses, the depth of skin cracks,
the degree of bacterial skin colonization and the patient’s
underlying comorbidities. Hence this lack of correlation does not
necessarily imply that the grading scale does not reflect disease
severity.
Long hospital stays (particularly those involving single rooms
and contact isolation) are expensive to the health care system, and
frustrating for patients. The 5 day decrease in length of stay which
we observed with the use of the grading scale, with no increase in
relapse rates, is substantial and represents a large cost saving.
Another potential advantage of our grading scale is that it may
help guide the duration and type of therapy for those clinicians
who are less experienced in the management of crusted scabies.
Given that crusted scabies is a rare condition in most settings, the
utility of such a grading scale for the average clinician is a good
reason for its use.
Ivermectin is an orally administered semi-synthetic macrocyclic
lactone antibiotic. It is approved for the treatment of scabies in
France but is not licensed for the treatment of scabies in the
United States, United Kingdom or Australia. However is it
commonly used off-label for the treatment of scabies in Australia.
Ivermectin does not sterilize scabies eggs so multiple doses are
recommended to kill newly hatched mites [10]. Ivermectin has
been associated with adverse effects in some studies, which
emphasizes the benefit of using a grading scale that allows for the
titration of the total dose of ivermectin and in our study a possible
reduction in number of doses in patients with milder disease.
Intensive ivermectin use may also increase the probability of the
mite developing resistance especially in patients with multiple
relapses [24].
This study was planned prospectively, but the grading scale had
to be calculated retrospectively in 40% of patients, introducing
possible inaccuracies in the calculated scores. Fortunately, a
detailed clinical assessment was recorded in the medical record for
all patients, and thus we were able to calculate the score for all
patients without having to interpolate missing data. Despite this,
the score calculated at the time of clinical assessment is likely to be
more accurate; retrospectively calculated scores may have
underestimated severity in certain areas such as degree of crusting
and shedding. However, this would not affect the overall
conclusions regarding the use of the score, as the outcome
measures were not the scores themselves, but objective measures
including length of hospital stay and need for re-admission. Our
population differs substantially from some others in whom crusted
scabies has been reported to occur. Hence it is important for the
grading scale to be studied in other populations before concluding
that it is useful in all settings.
We have described a simple clinical grading scale to aid in the
management of patients with crusted scabies. If validated in other
settings, its use is likely to improve the management of crusted
scabies and may lead to a decreased length of required hospital stay
and of ivermectin treatment, without compromising outcomes.
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Table 1. Demographics and comorbidities.
n %
Indigenous 49 100
Male 29 59
Age (years)a 44.1 [34.6–53.5] -
Remote-dwelling 39 80
Diabetes 11 22
Chronic Renal Disease 8 16
Chronic liver disease 6 12
Iatrogenic immunosuppression 3 6
Hazardous alcohol use 24 48
HTLV-1 infection 5 10
HIV infection 0 0
aMedian [IQR].
doi:10.1371/journal.pntd.0002387.t001
Table 2. Grading scale, disease severity, and outcomes.
Mild Moderate Severe Total Pd
n 8 24 17 49
Bacteraemica 1 (13%) 4 (17%) 2 (12%) 7 NS
Peak CRPb (units) 46 [28-145] 31 [6-58] 49 (29-54) - NS
Nadir albumin
(g/dL)c
33 [27-36] 31 [22.5-34.5] 26 (23-31) - NS
ICU admissiona 1 (13%) 2 (8%) 2 (12%) 5 NS
Required
readmissiond
1 (13%) 11 (46%) 11 (65%) 23 0.03
Length of stay
(days)e,f
13 [6-21] 14 [11-17] 15 [13-16) NS
Doses of
ivermectine,f
3 [3-3] 5 [5-5] 7 [7-7] 0.001
an(%).
bHighest plasma C-reactive protein during the hospital admission (median
[IQR]).
cLowest serum albumin value during the hospital admission (median [IQR]).
dP value for moderate and severe combined, compared with mild, except where
indicated.
eMedian [IQR].
fP value based on Kruskall Wallis test comparing the three groups.
doi:10.1371/journal.pntd.0002387.t002
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